Nelotanserin - Axovant Sciences

Drug Profile

Nelotanserin - Axovant Sciences

Alternative Names: APD-125; RVT-102

Latest Information Update: 23 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; Axovant Sciences
  • Class Sleep disorder therapies; Small molecules
  • Mechanism of Action Serotonin 2A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lewy body disease
  • Discontinued Insomnia

Most Recent Events

  • 19 Jun 2017 Nelotanserin receives Fast Track designation for Lewy body disease [PO,Tablet] (In adolescents, In children) in USA
  • 19 Jun 2017 Nelotanserin receives Fast Track designation for Lewy body disease [PO,Tablet] (In the elderly, In adults) in USA
  • 13 Feb 2017 Interim efficacy and adverse events data from a phase II trial in Lewy body dementia released by Axovant Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top